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An 111In-labelled bis-ruthenium(II)
dipyridophenazine theranostic complex: mismatch
DNA binding and selective radiotoxicity towards
MMR-deficient cancer cells†
Martin R. Gill, *ae Michael G. Walker,b Sarah Able, a Ole Tietz, a
Abirami Lakshminarayanan, ad Rachel Anderson,a Rod Chalk,c Afaf H. El-Sagheer,df
Tom Brown, d Jim A. Thomas b and Katherine A. Vallis *a
Theranostic radionuclides that emit Auger electrons (AE) can generate highly localised DNA damage and the
accompanying gamma ray emission can be used for single-photon emission computed tomography
(SPECT) imaging. Mismatched DNA base pairs (mismatches) are DNA lesions that are abundant in cells
deficient in MMR (mismatch mediated repair) proteins. This form of genetic instability is prevalent in the
MMR-deficient subset of colorectal cancers and is a potential target for AE radiotherapeutics. Herein we
report the synthesis of a mismatch DNA binding bis-ruthenium(II) dipyridophenazine (dppz) complex that
can be radiolabelled with the Auger electron emitting radionuclide indium-111 (111In). Greater stabilisation
accompanied by enhanced MLCT (metal to ligand charge-transfer) luminescence of both the bis-
Ru(dppz) chelator and non-radioactive indium-loaded complex was observed in the presence of a TT
mismatch-containing duplex compared to matched DNA. The radioactive construct [111In]In-bisRu(dppz)
([111In][In-2]4+) targets cell nuclei and is radiotoxic towards MMR-deficient human colorectal cancer cells
showing substantially less detrimental effects in a paired cell line with restored MMR function. Additional
cell line studies revealed that [111In][In-2]4+ is preferentially radiotoxic towards MMR-deficient colorectal
cancer cells accompanied by increased DNA damage due to 111In decay. The biodistribution of [111In][In-
2]4+ in live mice was demonstrated using SPECT. These results illustrate how a Ru(II) polypyridyl complex
can incorporate mismatch DNA binding and radiometal chelation in a single molecule, generating
a DNA-targeting AE radiopharmaceutical that displays selective radiotoxicity towards MMR-deficient
cancer cells and is compatible with whole organism SPECT imaging.
Introduction
The aim of targeted radionuclide therapy (TRT) is to employ
a carrier molecule conjugated to a suitable radioisotope to
deliver a radiotoxic dose of ionising radiation (IR) specically to
cancer cells while sparing healthy tissue.1,2 Clinical TRT radio-
pharmaceuticals incorporating long-range b-emitting
radioisotopes most commonly target cell surface receptors or
transporters.3 However, short-range Auger electrons (AE)
emitted by radionuclides such as 111In (half-life ¼ 2.8 days) are
of interest as they provide high ionisation densities at the site of
decay.4 With sufficient uptake into the cell nucleus, AEs are able
to induce radiotoxic DNA damage in the form of single-strand
and double-strand breaks (SSBs and DSBs), with DSBs exhibit-
ing greater cytotoxicity.5 Due to the short path-length of AEs in
biological media, it follows that AEs directed to specic regions
within the genome will efficiently provide cell-specic radio-
toxicity6–8 and that nonspecic radiotoxicity to neighbouring
cells can be limited.9 Furthermore, many Auger electron emit-
ting radionuclides also emit gamma ray radiation, making them
compatible with whole-body SPECT imaging. This dual
imaging/therapy capacity signies AE radiotherapeutics as
theranostics whereby initial diagnosis, tumour targeting and
also response of the site(s) of disease to treatment may be
determined by non-invasive imaging.10
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The mismatch repair (MMR) pathway consists of a series of
proteins that act to correct DNA base pair mismatches (non-
Watson–Crick base pairs) generated from errors during leading-
and lagging-strand replication.11 Direct evidence for the accu-
mulation of mismatches has been shown in MMR-defective
yeast strains12 and the mutation signatures in CRISPR-
modied human tumour cell organoids is consistent with an
approximately 2000 greater level of mismatches in MMR-
defective than MMR-procient cells.13 A signicant percentage
of all colorectal cancers (15%) are thought to be lacking in MMR
function14 and MMR-deciency has been associated with
resistance to common chemotherapeutics.15,16 Work utilising
small molecules specically developed for high affinity binding
to mismatch sequences17–20 or employing drugs identied
through repurposing screens have discovered therapeutic
candidates with enhanced selectivity towards MMR-decient
human colorectal cancers.21–23 Given the success of this
approach, we hypothesised that if an AE-emitting radionuclide
could be targeted to a mismatch site, the resultant DNA damage
would result in enhanced radiotoxicity in MMR-decient colo-
rectal cancer cells.
Ruthenium(II) polypyridyl complexes (RPCs) containing inter-
calating ligands such as dppz (dppz ¼ dipyrido[3,2-a:20,30-c]phena-
zine) possess high DNA binding affinities,24 including tunable
selectivity for mismatch-containing DNA sequences,25–28 and also
enhanced metal to ligand charge-transfer (MLCT) luminescence
upon binding that is compatible with uorescent cell imaging
techniques.29–31 In our ongoing studies into the biological activity of
RPCs, we have found Ru(II) metallointercalators can inhibit DNA
replication in cancer cells32,33 while also functioning as radio-
sensitizers for IR, including alongside AE radiopharmaceuticals.34
In particular, suitably tethered oligonuclear Ru(dppz) complexes
can display high DNA binding affinities accompanied by enhanced
cell uptake relative tomononuclear analogues.35,36Consequently, we
set out to use this architecture as a novel class of radiometal
chelator to deliver an AE-emitting radionuclide to cellular DNA.
Here, we report a bis-Ru(dppz) DNA-binding RPC designed for
selectivity towards mismatch DNA and the ability to be radio-
labelled with the AE-emitting radiometal 111In. We show this
experimental radiopharmaceutical exhibits preferential radio-
toxicity towards MMR-decient cancer cells and also is suitable for
use in the nuclear medicine imaging technique of SPECT in live
organisms.
Results
Chemistry and radiolabelling
The monometallic precursor [Ru(tpm)(dppz)(4-(aminomethyl)
pyridine)]2+ (tpm ¼ tris-(1-pyrazolyl)methane), [1]2+, was
prepared from an established pathway37 and reacted with
cDTPA (cyclic diethylenetriaminepentaacetic acid anhydride).
The crude product was analysed by reverse-phase HPLC and the
largest peak collected, which was determined to be the dinu-
clear complex H3[2]
4+ (Scheme 1). [1]2+ and H3[2]
4+ were
analyzed by HPLC and characterised by high resolution mass
spectrometry and NMR (Fig. S1 and S2 in the ESI†). As [1]2+
contains an achiral Ru(II) centre, the structure of H3[2]
4+ is two
Ru(II) centres each containing the intercalating ligand dppz
axial to the (aminomethyl)pyridine linker. The 111In chelator
DTPA38 is then at the centre of the 4-(aminomethyl)pyridine-
based linker ligand between each Ru(dppz) group.
The non-radioactive (“cold”) In(III)-coordinated complex, [In-
2]4+, was prepared by reaction of H3[2]
4+ with InCl3. Successful
indium conjugation and purity of [In-2]4+ was conrmed by
high resolution mass spectrometry and HPLC (Fig. S3†). Radi-
olabelling of H3[2]
4+ with 111In was efficient under mild condi-
tions, as determined by instant thin layer chromatography
(iTLC) (Fig. S4†). HPLC analysis of [111In][In-2]4+ demonstrated
radiochemical purity of >98% and co-injection with [In-2]4+
conrmed the identity of the radioactive species as [111In][In-
2]4+ (Fig. 1). Specic activities of 10 MBq mg1 (apparent specic
Scheme 1 Preparation of bisRu(dppz)–DTPA chelator H3[2]
4+ and
subsequent radiolabelling with the Auger electron emitting radionu-
clide 111In to form [111In][In-2]4+.
Fig. 1 (a) HPLC chromatograms of co-injection of [111In][In-2]4+ and
[In-2]4+ showing radioactivity (top) and absorbance (350 nm, bottom).
(b) HPLC chromatogram of H3[2]
4+ (absorbance at 350 nm). Chro-
matograms obtained using HPLC method B.
This journal is © The Royal Society of Chemistry 2020 Chem. Sci., 2020, 11, 8936–8944 | 8937
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molar activities of >20 GBq mmol1) were achieved routinely.
[111In][In-2]4+ was stable in aqueous solution at room temper-
ature, with no 111In dissociation for up to 72 h storage (Fig. S5†).
No signicant dissociation of 111In3+ from [111In][In-2]4+ in cell
media at 37 C, in the presence of serum, or competing metal
ions Fe3+ or Zn2+ was observed (Fig. S6†).
DNA binding and TT mismatch selectivity
All complexes demonstrated a distinctive increase of MLCT
emission upon addition of CT-DNA (calf thymus DNA), indica-
tive of DNA intercalation of the dppz moiety,29 with [In-2]4+
displaying the greatest emission enhancement (Fig. 2a). DNA
binding constants, Kb, were obtained by tting binding curves
from luminescence DNA titrations to the McGhee von Hippel
binding model (Fig. S7 and Table S1†).39 The trimetallic species
[In-2]4+ (Kb ¼ 1.1  10
6 M1) demonstrated greater affinity for
CT-DNA than the mononuclear complex [1]2+ (Kb ¼ 3.8  10
5
M1), unsurprising as [In-2]4+ contains two Ru(dppz) groups
and a greater overall positive charge. The native H3[2]
4+ (Kb ¼
2.4  105 M1) chelator showed a lower binding affinity than
[In-2]4+, indicating that indium-loading acts to increase DNA
affinity. As H3[2]
4+ will exist as the monocationic [2]+ species in
aqueous solution at pH 7 due to deprotonation of the three
hydroxyl groups of the DTPA linker, this may be rationalised by
the greater positive charge of [In-2]4+.
Next, selectivity for mismatched DNA was examined. Other
work has shown that increasing the steric demand of ancillary
ligands attached to the Ru(dppz) results in complexes that
preferentially bind to mismatches.25–28 We reasoned that [1]2+
and H3[2]
4+ may show similar selectivity as each possess the
bulky tpm ancillary ligand and a Ru(dppz) centre(s). Employing
a DNA hairpin containing a single variable base pair, a greater
relative emission for [1]2+ or H3[2]
4+ for every hairpin containing
a mismatch base pair (GG, CA, AA, TT and CC) compared to
a well-matched AT or GC base pair was seen (Fig. 2b). Although,
on initial inspection, these results appear similar to work
employing the related DNA mismatch “light switch” molecule
[Ru(Me4phen)2(dppz)]
2+ (Me4phen ¼ 3,4,7,8-tetramethyl-1,10-
phenanthroline),27 a signicant increase for the TT mismatch-
containing sequence was apparent for H3[2]
4+. This behavior
was not observed for [Ru(Me4phen)2(dppz)]
2+ and is a relatively
rare nding for mismatch-interactive compounds.20
The emissive properties of the compounds towards a 10-mer
oligomeric DNA duplex containing a single TT mismatch was
examined (Fig. 2c and S8†). Compared to the well-matched
sequence, H3[2]
4+ showed an enhanced emission intensity for
the TT mismatch-containing duplex (Fig. 2c and d), suggesting
a stronger binding interaction due to presence of the mismatch.
Thermal denaturation studies of each DNA duplex in the
absence and presence of each complex were performed to
further elucidate this matter. Ligand-induced changes of DNA
melting temperature (DTm) indicate that all the Ru(II) complexes
increased the melting temperature of the matched duplex (DTm
values of 3.6 0.3, 4.5 0.3 and 5.0 0.4 C for [1]2, H3[2]
4+ and
[In-2]4+ respectively, Fig. 2e). Notably, the increase in Tm values
with mismatch-containing duplexes due to incubation with
each Ru(II) complex were signicantly larger than for the well-
matched sequence (DTm values 7.0  0.2, 10.6  0.3 and 12.3
 0.2 C for the addition of [1]2, H3[2]
4+ and [In-2]4+ to the
mismatch-containing sequence respectively, Fig. 2e), indicating
greater stabilisation of the duplex when the mismatch TT base
pair is present. This increased mismatch stabilisation was more
pronounced for H3[2]
4+ and [In-2]4+ than [1]2+; an observation
that is in alignment with the luminescence data. [In-2]4+ did not
demonstrate mismatch selectivity with the hairpin structure
(Fig. 2b), the luminescence and DTm values for [In-2]
4+ and
Fig. 2 (a) MLCT luminescence of Ru(II) complexes (30 mM) without (w/
o) and with calf-thymus DNA (80 mM) (lex ¼ 405 nm). (b) Relative
emission intensities for [1]2+, H3[2]
4+ or [In-2]4+ (30 mM) with the
addition of DNA hairpins containing a single variable XY base pair (3 mM,
top). Data for each compound normalised to XY ¼ AT emission
intensity (dashed line). Mean of two independent replicates  S.D. (c)
Emission spectra of H3[2]
4+ or [In-2]4+ with 10-mer matched DNA
duplex or 10-mer containing a single TT mismatch site (duplex
sequences shown at top, 30 mM complex, 3 mM DNA duplex). (d)
Integrated emission intensities TT mismatch and matched DNA with
the addition of [1]2+, H3[2]
4+ or [In-2]4+ (3 mM DNA duplexes, 30 mM
complexes). Average of two independent experiments  S.D. (e) DTm
(C) values for match or TTmismatch duplexes (3 mM) with the addition
of complexes (30 mM), determined by thermal denaturation studies
(each Tm average of six successive melting curves per condition). Tm
(match)¼ 47.43 C, Tm (TT mismatch)¼ 33.62
C. Error bars represent
the combined standard uncertainty. Conditions: 10 mM phosphate
buffer, 200 mM NaCl, pH 7.0. lex ¼ 405 nm, lem ¼ 600–800 nm for
[1]2+, H3[2]
4+ and [In-2]4+.
8938 | Chem. Sci., 2020, 11, 8936–8944 This journal is © The Royal Society of Chemistry 2020
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H3[2]
4+ showed comparable increases for the 10-mer duplex
containing a TT mismatch over the well-matched sequence
(Fig. 2c–e). This indicates that In-coordination does not inter-
fere with preferential TTmismatch stabilisation within a duplex
environment. The contrasting results obtained for the hairpin
DNA likely indicates altered geometric or entropic contributions
to binding as a result of In-coordination decreasing the exi-
bility of the molecule.
Cellular uptake and cytotoxicity of non-radioactive complexes
Inductively coupled plasma mass spectroscopy (ICP-MS) anal-
ysis of HCT-116 human colorectal cancer cells treated with [1]2+,
H3[2]
4+ or “cold” [In-2]4+ showed relatively low cellular uptake of
each complex with a signicant proportion of ruthenium
content detected in isolated nuclear fractions (Fig. 3a). For
example, cells treated with 50 mM [1]2+ for 2 h, 5.5 3.6 and 17.9
 3.0 ng Ru per mg cell protein was detected in the cytosol and
nucleus, respectively. Although intracellular Ru content was
comparable for all complexes, H3[2]
4+ and “cold” [In-2]4+ are
both dinuclear Ru complexes and so therefore have decreased
uptake of each molecule compared to the mononuclear [1]2+.
These results are in contrast to recent results employing
a hydrophobic linker between Ru(tpm)(dppz) centres36 and are
likely explained by the hydrophilicity of DTPA acting to decrease
cellular uptake. Comparable results for H3[2]
4+ and [In-2]4+ were
seen (cytosolic Ru content: 8.5 3.0 and 8.4 0.9 ng Ru per mg
cell protein for H3[2]
4+ and [In-2]4+ respectively. Nuclear Ru
content: 7.2  4.9 and 12.2  3.7 ng Ru per mg cell protein for
cells treated with H3[2]
4+ and [In-2]4+ respectively, Fig. 3a),
indicating that In-coordination did not substantially alter
cellular uptake or subcellular distribution of the Ru(II) scaffold.
MLCT emission detectable by confocal laser scanning micros-
copy (CLSM) also provides evidence of in cellulo DNA binding.40
Evidence of MLCT luminescence was observable in the nuclei of
live HCT-116 cells treated with [1]2+ or H3[2]
4+ (Fig. 3b), which
does supply evidence that nuclear DNA is targeted. Intracellular
luminescence was generally poor (Fig. S9†), preventing more
extensive use of this technique. Low intracellular MLCT emis-
sion is likely due to the low cellular uptake of the complexes. For
example, the RPC nuclear imaging agent [Ru(phen)2(tpphz)]
2+
(phen ¼ 1,10 phenanthroline, tpphz ¼ tetrapyridophenazine)
demonstrates 100-fold greater uptake than the complexes
within this work.33 Erratic nuclear staining appears to be
a common feature of Ru(dppz) complexes, even for molecules
with more pronounced “light switch” effects.24,30
[1]2+ and H3[2]
4+ demonstrated low cytotoxicity, with 72 h half-
inhibitory IC50 concentrations >50 mM in all lines tested (Fig. S10
and Table S3†). [In-2]4+ showed mild cytotoxicity towards HCT-116
andHeLa cells, approximately ve-fold less cytotoxic than cisplatin
in HCT-116 cells (IC50 concentrations of [In-2]
4+: 34 and 32 mM
towards HCT-116 and HeLa cells, respectively. Cisplatin: 6.6 and
0.5 mM towards HCT-116 and HeLa cells, respectively, Table S3†).
Unlike more potent anti-proliferative Ru(II) metal-
lointercalators,32,33 no signicant enhancement of the DSB damage
marker gH2AX (H2AX phosphorylated at Ser139) (ref. 41) above
levels found in untreated control cells was seen in response to
treatment with any Ru(II) compound (Fig. 3c).
Cellular uptake of [111In][In-2]4+
Cellular uptake of the radiolabelled complex [111In][In-2]4+
(log P ¼ 2.46  0.26) was examined in three human colorectal
cancer cell lines: DLD-1 and HCT-116, which are both MMR-
decient and hypermutated, and HT-29, which is MMR pro-
cient and nonhypermutated (Table S2† and ref. 42). These
results showed greater uptake of [111In][In-2]4+ than the non-
coordinated “free” [111In]In3+ in all cell lines tested and the
greatest radioactivity was seen in the isolated nuclear fractions,
indicating successful nuclear targeting by [111In][In-2]4+
(Fig. 3d). A comparable subcellular distribution of radioactivity
to intracellular ruthenium content (by ICP-MS) in HCT-116 cells
for [111In][In-2]4+/[In-2]4+ is consistent with 111In/In-
coordination to H3[2]
4+ remaining stable in cells. Interest-
ingly, elevated nuclear uptake of [111In][In-2]4+ was apparent in
DLD-1 cells, with approximately four-fold greater levels of
radioactivity in this fraction compared to HCT-116 or HT-29
cells (Fig. 3d).
Radiotoxicity of [111In][In-2]4+
Employing the DLD-1 and DLD-1 + Chr2 paired cell lines, where
DLD-1 + Chr2 cells are DLD-1 cells with genetically restored
Fig. 3 (a) Intracellular Ru content of HCT-116 cells treated with [1]2+,
H3[2]
4+ or [In-2]4+ (50 mM, 2 h), as determined by ICP-MS. Cells were
separated into cytosol and nuclear fractions before analysis (see inset
for verification of successful fractionation). Mean of triplicates  S.D.
(b) Confocal laser scanning micrograph of HCT-116 cells treated with
[1]2+ or H3[2]
4+ (100 mM, 4 h) showing nuclear MLCT emission. Scale
bars ¼ 20 mm. (c) Western blotting for gH2AX levels in HCT-116 cells
after 24 treatment with cisplatin (Cis, 7 mM) or Ru(II) compounds (50
mM). b-Actin was used as a loading control. NT ¼ not treated. (d)
Cytosolic and nuclear uptake of [111In][In-2]4+ in DLD-1, HCT-116 or
HT-29 cells (1 MBq ml1, 2 h), as determined by radioactivity in cyto-
solic and nuclear subcellular fractions. An equivalent amount of
radioactivity of [111In]In3+ was included for comparative purposes.
Mean of triplicates  S.D.
This journal is © The Royal Society of Chemistry 2020 Chem. Sci., 2020, 11, 8936–8944 | 8939
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MMR function, greater radiotoxicity of [111In][In-2]4+ towards
the parental DLD-1 cells was apparent with reduced effects
towards the MMR restored DLD-1 + Chr2 cells (Fig. 4a). Low
radiotoxicity was observed for equivalent doses of free [111In]
In3+ in both cell lines. MMR status in the matched cell line pair
has no impact on cell survival in response to external beam g-
rays, indicating no change in inherent radiosensitivity due to
the restoration of MMR function (Fig. 4b). As there was negli-
gible cytotoxicity from the non-radioactive complex at the low
concentrations of H3[2]
4+ employed (Fig. S10 and Table S3†),
these ndings are consistent with the potency of [111In][In-2]4+
being attributable to 111In-induced radiotoxicity. [111In][In-2]4+
was similarly radiotoxic towards MMR-decient HCT-116 cells
but showed substantially reduced radiotoxicity towards the
MMR-procient HT-29 cells and normal WI-38 human bro-
blasts (Fig. 4c and d). Examining levels of DNA damage in cells
treated with [111In][In-2]4+, greater expression of gH2AX was
seen in DLD-1 and HCT-116 cell lines compared to HT-29 cells
(Fig. 4e). Negligible DNA damage generation as a result of
treatment with [111In]In3+ or the non-radiolabelled H3[2]
4+
(Fig. 4e) provided further evidence of the targeted radiotoxicity
of [111In][In-2]4+. gH2AX foci formation due to [111In][In-2]4+
treatment was conrmed in HCT-116 cells by immunouores-
cence (Fig. S11†).
Metal complexes can also function as radiosensitizers for
DNA-damaging IR, either as a result of their biological activity
and/or the presence of an atom with a high Z number.43 Treat-
ment of HCT-116 cells with 50 mM H3[2]
4+ or “cold” [In-2]4+ did
not result in signicant enhancement of cellular sensitivity to g-
rays (Fig. S12 and Table S4†), indicating that neither the
chelator nor non-radioactive In-coordinated complex have
potent radiosensitizing effects. Considering the low
Fig. 4 (a) Radiotoxicity of [111In][In-2]4+ towards DLD-1 (MMR-deficient) or DLD-1 + Chr2 (MMR restored) human colorectal cancer cell lines, as
determined by clonogenic survival assay (24 h incubation time). Mean  S.D. of three independent experiments, where each experiment was
performed in triplicate. (b) Clonogenic survival of DLD-1 or DLD-1 + Chr2 cells after irradiation with 137Cs-g-rays. Mean  S.D. of three inde-
pendent experiments, where each experiment was performed in triplicate. (c) Radiotoxicity of [111In][In-2]4+ towards MMR-deficient HCT-116 or
MMR-proficient HT-29 cancer cell lines, as determined by clonogenic survival assay (24 h incubation time). Mean  S.D. of triplicates. (d) Cell
viability of WI-38 normal human fibroblasts treated with [111In][In-2]4+ (24 h incubation time, cell viability measured by MTT assay 5 days after
complex removal). Mean S.D. of triplicates. (e) DNA damage in cell lines treated with [111In][In-2]4+ (10 MBqml1, 6 h), as determined by gH2AX
levels. Mean of two technical repeats  S.D. Specific activity of [111In][In-2]4+ ¼ 20 MBq mg1, corresponding to a concentration of H3[2]
4+ < 0.5
mM in all experiments. Equivalent doses of [111In]In3+ (by activity ml1, as [111In]In citrate) or H3[2]
4+ (by concentration) were included for
comparative purposes, where indicated.
8940 | Chem. Sci., 2020, 11, 8936–8944 This journal is © The Royal Society of Chemistry 2020
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concentrations of H3[2]
4+ employed in cell survival studies (<0.5
mM), a “self-radiosensitizing” effect contributing to the radio-
toxicity of [111In][In-2]4+ is unlikely.
SPECT imaging and biodistribution
In addition to AEs, 111In also emits g-rays, making the radio-
nuclide compatible with SPECT imaging, a technique
commonly used to assess biodistribution of an 111In-labelled
radiopharmaceutical in living organisms.10 To assess the
compatibility of [111In][In-2]4+ with this technique, an explor-
atory SPECT imaging study in DLD-1 tumour-bearing mice was
conducted. SPECT images were acquired from continuous data
acquisition 10–70 minutes post intravenous injection (p.i.) with
[111In][In-2]4+. As shown in Fig. 5a and S13 in the ESI,† [111In][In-
2]4+ accumulated primarily in the liver and bladder with
a strong signal in both organs. Biodistribution of [111In][In-2]4 +
24 h p.i. revealed high liver retention (21.1% injected dose per
gram, I.D./g) accompanied by low accumulation in all other
regions (<2.4% I.D. per g for all other organs tested, Fig. 5b).
Taken together, these results indicate that the liver is the
primary organ targeted by [111In][In-2]4+ in vivo. The total levels
of radioactivity recovered from tumours were low (0.09% I.D.
per g1, Fig. 5b), indicating poor inherent tumour-targeting
properties of the compound.
Discussion and conclusions
In the area of designing small molecules to bind non-canonical
DNA structures, DNA mismatch-interactive compounds have
shown encouraging preferential activity towards MMR-decient
colorectal cancers.44 While denitive data on the lifetime of
mismatches themselves (as opposed to their mutation signa-
tures) in human cells is currently lacking, a genome-wide study
in yeast indicated repair of TT mismatches to be one of the least
efficient of all mismatch base pairings.12 Preferential stabilisa-
tion of a TT mismatch is a relatively rare nding for mismatch-
interactive compounds described to date.20 Related to the
chemical design of [2]+, other molecules that preferentially bind
TT mismatches likewise employ a bis-intercalating design. This
includes a bis-naphthalene macrocycle “threading” molecule,45
a triaminotriazine–acridine conjugate which acts by intercala-
tion of the acridine group along with hydrogen bonding46 and
a vinyldiaminotriazine–acridine conjugate for the selective
alkylation of TT mismatched DNA.47 Although our study was
limited to a short hairpin and TT mismatch-containing 10-mer
duplex, it would be interesting to examine the stabilisation of
a greater range of mismatch-containing duplex sequences by
these Ru(II) complexes. Considering X-ray crystal structures of
RPC-DNA co-crystals have proven invaluable in understanding
binding geometries and specicities,48–51 X-ray crystallography
studies employing [2]+ and [In-2]4+ alongside matched and
mismatch-containing duplexes would be similarly useful.
Our results indicate that [111In][In-2]4+ generates preferential
DNA damage and accompanying decrease in cell survival in
MMR-decient cancer cells by 111In decay. To our knowledge,
this is the rst example of a radiopharmaceutical exhibiting
selective activity towards MMR-decient cancer cells. Evidence
of nuclear targeting by [111In][In-2]4+, the ability of [In-2]4+ to
preferentially bind and stabilise TT mismatched DNA along
with demonstrable DNA damage foci in MMR-decient cancer
cells are ndings that would agree with the notion that [111In]
[In-2]4+ generates DSB damage at these specic regions. These
results are consistent with biological studies demonstrating
Auger electrons from 111In generate radiotoxic DSB damage
when in close proximity to DNA52 and computation modelling
showing DSBs induced by 111In are within 4 nm from the site of
decay on the central axis of DNA.53 Further biochemical studies
on DNA damage generated by [111In][In-2]4+ are required to
examine this hypothesis in more detail.
Although the In-chelator H3[2]
4+ does bind DNA, it had
negligible cytotoxicity and does not generate signicant intra-
cellular DNA damage, which is advantageous in its use as
a benign carrier of 111In to the target DNA molecule. This
approach is in contrast to studies examining cytotoxic organic
intercalators conjugated to 99mTc.54–56 As 99mTc is an AE-
emitting radiometal with lower efficacy than 111In,9 in these
cases the cytotoxic effects of the organic intercalator dominates
and high specic activities of the radiopharmaceutical are
required for radiotoxicity. Although these results are encour-
aging, enhancing the selectivity of H3[2]
4+ and [In-2]4+ towards
the mismatch-containing duplex versus well-matched sequence
is desirable for translational applications. As an example, this
could be achieved by chemical modication of the ancillary tpm
ligand to decrease affinity for well-matched DNA. The mismatch
selectivity of related complexes reported by Boynton, et al.
Fig. 5 (a) Representative SPECT/CT image of a mouse constructed fro-
m images taken 10–70 min after intravenous injection of [111In][In-2]4+
(8 MBq). L ¼ liver. B¼ bladder. T¼ DLD-1 xenograft tumour. (b) Ex vivo
radioactivity content of organs of mice 24 h after intravenous injection
of [111In][In-2]4+ expressed as the % of injected dose (at t ¼ 0 h) per gram
(n ¼ 3, mean  S.D.). Note break in y-axis.
This journal is © The Royal Society of Chemistry 2020 Chem. Sci., 2020, 11, 8936–8944 | 8941
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demonstrate that optimised targeting of these defects can be
accomplished.27,28
The use of radiolabelled compounds has proven invaluable
in drug design as this may provide insight into biodistribution,
tumour-targeting, pharmacokinetics and pharmacodynamics in
living organisms. Given the recent increase of interest in RPCs
as therapeutics,57–59 this has made understanding these prop-
erties highly topical. While the large, hydrophilic [In-2]4+ is
atypical of many RPCs tested in this capacity, the unexpected
nding of rapid uptake and retention of [111In][In-2]4+ in the
liver combined with low kidney uptake is signicant. This is in
stark contrast to the majority of organic radiometal chelators60
and may be compared directly to biodistribution results for
111In[In-DTPA] in mice where no signicant retention in any
organ was described.61 Examples of metal-based chelators for
radiometals are exceedingly rare,62 however, a structurally-
related gadolinium-labelled bis-platinum Pt(NH3)2Cl–DTPA
complex is known to demonstrate high kidney uptake by MRI
imaging.63 That an evidently different clearance pathway is used
by [111In][In-2]4+ is particularly interesting considering the
interest in RPCs as alternative therapeutics to platinum drugs
and also the fact that clinical use of cisplatin is limited by
nephrotoxicity.64 We also note with interest that high liver
uptake was reported for a hydrophobic mononuclear RPC by the
Gasser group,65 indicating this may be a general outcome for
RPCs. Chemical rerouting of an elimination pathway towards
hepatic clearance will aid further design of RPCs as non-
platinum chemo/radiotherapeutics, and indicates that hepato-
toxicity may be a concern for this class of chemical.
The low intrinsic tumour-targeting of [111In][In-2]4+ and
relatively high doses required for radiotoxicity present chal-
lenges. While increasing the hydrophobicity of [111In][In-2]4+
with hydrophobic ancillary ligands such as DIP (DIP ¼ 4,7-
diphenyl-1,10-phenanthroline) could increase cellular uptake,
related research has shown this approach leads to a decrease in
nuclear DNA targeting30,66 and results in potent – but non-
specic – cytotoxicity.65 Instead, a delivery mechanism may be
a more appropriate method to achieve sufficient tumour uptake
in vivo for the therapeutic potential of this molecule to be
assessed in more detail. One attractive option is bioconjugation
employing a cleavable linker to a peptide or antibody that
targets surface receptors overexpressed by cancers.67 Peptide
conjugation can substantially improve biodistribution and
pharmacokinetics of an administered agent68 and numerous
design strategies for metallo-drug peptide conjugation have
been outlined in a recent review.69 Finally, 111In radiopharma-
ceuticals are also compatible with drug-delivery approaches
such as liposome-encapsulation of the chelator before subse-
quent radiometal loading.70 A stimuli mediated delivery mech-
anism then achieves localised drug release and improved
tumour uptake.71 Future work will explore these concepts.
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